Interpretation of Ultrasound-Based Elastography Clinical Cutoffs
Rule-of-5s kPa interpretation for VCTE and standardized vendor-agnostic kPa and m/s thresholds for ARFI shear wave elastography.
Clinicians often use a 'Rule of 5s' to translate your kPa stiffness number into plain English. On a FibroScan (VCTE), a score of 5 kPa or lower is typically normal, anything under 10 kPa makes advanced chronic liver disease very unlikely, 10 to 15 kPa enters a watch-closely zone, 15 kPa or higher confirms advanced scarring, and 20 to 25+ kPa alerts your liver specialist to check for elevated vein pressure (portal hypertension), especially when paired with your platelet count.
Interpretation of LSM by VCTE™ (Baveno VII “Rule of 5s”)1,4
| VCTE™-LSM, kPa | Interpretation |
|---|---|
| ≤5 | High probability of being normal |
| <10 | Exclude cACLD: risk of LREs is negligible |
| ≥10 to <15 | Potential cACLD: risk of LREs starts to increase In the presence of platelets ≥150 × 109/L: exclude CSPH |
| ≥15 to <20 | Confirm cACLD: clinically relevant risk of LREs In the presence of platelets ≥150 × 109/L: exclude HRVs (<5% risk; endoscopy spared)4 |
| ≥20 to <25 | cACLD with potential CSPH (“gray zone” for CSPH)a |
| ≥25 | Assume CSPH in non-obese MASH (BMI <30 kg/m2); in obese MASH (BMI ≥30 kg/m2), apply ANTICIPATE-NASHb |
Interpretation of LSM Obtained Using ARFI-SWE1,2
| ARFI-SWE, kPa | ARFI-SWE, m/s | Interpretation |
|---|---|---|
| ≤5 | 1.3 | High probability of being normal1,2 |
| <9 | 1.7 | In the absence of other known clinical signs, rules out cACLD. If signs are present, further testing may be needed1,2 |
| 9–13 | 1.7–2.1 | Suggestive of cACLD; further testing is required for confirmation1,2 |
| >13 | 2.1 | Rules in cACLD1,2 |
| >17 | 2.4 | Suggestive of CSPH1,2 |
| >21 | 2.6 | High probability of CSPH1 |
Portal Hypertension Refinement: Obese MASH (ANTICIPATE-NASH) & Spleen Stiffness (SSM)4-6
| Tool / Consensus Rule | Key Thresholds | Clinical Action (Baveno VII & AASLD 2025 NILDA) |
|---|---|---|
| ANTICIPATE-NASH Model4,6 Obese MASH (BMI ≥30 kg/m2) |
Combines BMI + VCTE LSM + Platelets | Because VCTE ≥25 kPa alone overestimates CSPH in patients with BMI ≥30 kg/m2, use the ANTICIPATE-NASH nomogram to estimate true CSPH probability before initiating carvedilol / NSBB therapy4,6 |
| Spleen Stiffness Measurement (SSM)4,5 | ≤21 kPa: Rule out CSPH ≥50 kPa: Rule in CSPH |
Resolves the VCTE 15–25 kPa / obese MASH CSPH gray zone at the same bedside session and further reduces unnecessary screening endoscopies4,5 |